Nabumetone

A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.

Also Known As:

4-(6-Methoxy-2-naphthyl)-2-butanone; Apo-Nabumetone; Arthraxan; BRL 14777; Gen-Nabumetone; Listran; Mebutan; Nabucox; Nabumeton; Relafen; Relif; Relifex; Rhoxal-nabumetone; ApoNabumetone; Rhoxal nabumetone

Networked: 194 relevant articles (36 outcomes, 74 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Ketones: 2618
  - Butanones
    - Nabumetone: 194
      - 4-(6-methoxy-2-naphthyl)butan-2-ol

Experts

1.	Geba, Gregory P: 3 articles (02/2006 - 05/2004)
2.	Polis, Adam B: 3 articles (02/2006 - 05/2004)
3.	Palmer, R H: 3 articles (12/2001 - 01/2000)
4.	Gonzalo-Garijo, M A: 2 articles (01/2011 - 01/2007)
5.	Najarian, Daryl K: 2 articles (02/2006 - 05/2004)
6.	Petruschke, Richard A: 2 articles (02/2006 - 05/2004)
7.	Weaver, Arthur L: 2 articles (02/2006 - 11/2004)
8.	Kivitz, Alan J: 2 articles (11/2004 - 05/2004)
9.	Matsumoto, Alan K: 2 articles (11/2004 - 05/2004)
10.	Li, Duan: 2 articles (01/2004 - 11/2003)

Related Diseases

1.	Osteoarthritis 04/01/2000 - "Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety." 01/01/1984 - "A double-blind, placebo-controlled, crossover trial was carried out to assess the efficacy and tolerance of nabumetone in patients with osteoarthrosis of the hip or knee. " 02/01/2000 - "Nabumetone is a phototoxic nonsteroidal antiinflammatory drug used for the treatment of osteoarthritis. " 04/01/1999 - "Searle & Co., Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee. " 12/01/1997 - "Elderly patients with osteoarthritis demonstrate decreased elimination and increased plasma concentrations of nabumetone as compared with young healthy volunteers. "
2.	Rheumatoid Arthritis 04/01/2003 - "Once-a-day dosing with nabumetone has been shown to be effective in adults with rheumatoid arthritis. " 06/15/1990 - "[Evaluation of tolerability and efficacy of a nabumetone preparation in the treatment of patients with rheumatoid arthritis]." 10/30/1987 - "The safety and efficacy of nabumetone and placebo were compared in a three-week, multicenter, double-blind, randomized, parallel evaluation involving patients with class II or III definite or classical rheumatoid arthritis. " 10/30/1987 - "Forty-six patients with definite or classical rheumatoid arthritis were entered into a three-week, double-blind, randomized, parallel study of nabumetone, 1,000 mg at bedtime, compared with placebo. " 10/30/1987 - "Gastric tolerance to 1 g of nabumetone administered in a single nightly dose was assessed in two trials in patients with rheumatoid arthritis. "
3.	Pain (Aches) 01/01/1999 - "The nabumetone 1500-mg group showed significantly greater improvement than the placebo group in bodily pain and social functioning (P < 0.05), and in vitality and MCS score (P < 0.01). " 07/01/1997 - "Distribution of quality of sleep and inactivity stiffness scores also improved relative to placebo at week 2. At the last visit, nighttime pain scores were still significantly better for patients receiving Naprelan versus nabumetone and placebo. " 07/01/1997 - "The nabumetone-treated group showed significant improvement over the placebo-treated group in only one primary assessment: mean change from baseline in patient's global assessment of OA at week 2. At week 2, significant differences favoring Naprelan versus nabumetone and placebo were measured in overall distribution of scores for joint tenderness and nighttime pain. " 11/01/1992 - "At the end point, nabumetone treated patients exhibited significant improvement in pain, Ritchie articular index, and duration of morning stiffness when compared to baseline. " 12/01/2009 - "This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA."
4.	Soft Tissue Injuries (Soft Tissue Injury) 04/01/1993 - "To review the pharmacology, pharmacokinetic disposition, dosage recommendations, adverse effects, drug interactions, and efficacy of nabumetone in patients with selected rheumatic disorders and soft-tissue injuries. " 10/30/1987 - "Nabumetone in the treatment of skin and soft tissue injury." 01/01/2004 - "The clinical efficacy of nabumetone has also been evaluated in patients with ankylosing spondylitis, soft tissue injuries and juvenile RA. " 04/01/1993 - "Nabumetone also has been studied in ankylosing spondylitis and soft-tissue injuries. " 10/30/1987 - "Nabumetone, a new nonsteroidal anti-inflammatory agent, has been evaluated for the treatment of skin and soft tissue injury, including sports injury, in clinical trials involving nearly 1,000 patients. "
5.	Ulcer 04/01/2013 - "Nabumetone inhibited stress-induced ulcer index at 25-mg/kg dose but stimulated dose-dependently mucus secretion. " 12/01/2001 - "In contrast, nabumetone impaired ulcer healing only at very high doses." 11/01/1992 - "The cumulative incidence of nabumetone-induced perforations, ulcers, or bleeds varied from 0.02 to 0.95%. " 11/01/1992 - "The ulcer incidence after therapy with nabumetone, however, is far below the reported range. " 04/01/2000 - "In the pooled analysis, nabumetone was associated with a significantly lower total incidence of ulcers and bleeding events, and a significantly lower incidence of complications associated with these events."

Related Drugs and Biologics

1.	Naproxen (Naprosyn)
2.	Ibuprofen (Motrin)
3.	Aspirin (Acetylsalicylic Acid)
4.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
5.	Diclofenac (SR 38)
6.	Misoprostol (Cytotec)
7.	Indomethacin (Indometacin)
8.	rofecoxib (Vioxx)
9.	Etodolac (Lodine)
10.	Celecoxib (Celebrex)

Related Therapies and Procedures

1.	Splenectomy
2.	Length of Stay
3.	Therapeutics
4.	Intravenous Administration
5.	Pain Management